表皮生长因子受体通路抑制在非小细胞肺癌中的一、二线治疗策略。
Primary and secondary therapeutic strategies for EGF receptor pathway inhibition in non-small-cell lung cancer.
机构信息
Rush University Medical Center, 1725 W Harrison Street, Chicago, IL 60612-3838, USA.
出版信息
Expert Rev Anticancer Ther. 2010 Oct;10(10):1589-99. doi: 10.1586/era.10.104.
As diagnostic and therapeutic options increase, strategies for the treatment of non-small-cell lung cancer (NSCLC) are becoming more tailored for specific patient subpopulations and individual patients. The introduction of therapy targeted against the EGF receptor (EGFR) pathway has provided new treatment options for select patients with NSCLC. However, more than half of unselected NSCLC patients will fail to achieve disease stabilization on an EGFR tyrosine kinase inhibitor (TKI), and secondary resistance is observed in virtually all patients who initially respond or achieve disease stabilization. Efforts are underway to identify clinical and molecular predictors in patients who may benefit from treatment with EGFR TKIs. Recent strategies for targeting the EGFR pathway include combining EGFR TKIs with newer agents and developing second-generation irreversible EGFR TKIs, which may be used in patients who have failed treatment with first-generation EGFR TKIs.
随着诊断和治疗选择的增加，非小细胞肺癌（NSCLC）的治疗策略越来越针对特定的患者亚群和个体患者。针对表皮生长因子受体（EGFR）途径的治疗方法的引入为 NSCLC 的某些患者提供了新的治疗选择。然而，超过一半的未经选择的 NSCLC 患者在 EGFR 酪氨酸激酶抑制剂（TKI）上无法实现疾病稳定，并且几乎所有最初有反应或疾病稳定的患者都会出现继发性耐药。目前正在努力确定可能从 EGFR TKI 治疗中受益的患者的临床和分子预测因素。最近针对 EGFR 途径的策略包括将 EGFR TKI 与新型药物联合使用，并开发第二代不可逆 EGFR TKI，这些药物可用于第一代 EGFR TKI 治疗失败的患者。
Zotero 插件